Another treatment for MS is the amino acid threonine
Spot the double (or triple or quadruple) speak.
To determine whether the naturally occurring amino acid threonine, a potential precursor for glycine biosynthesis in the spinal cord, has an effect on spasticity in multiple sclerosis, 26 ambulatory patients were entered into a randomized crossover trial. Threonine administered at a total daily dose of 7.5 g reduced signs of spasticity on clinical examination, although no symptomatic improvement could be detected by the examining physician or the patient. In contrast to the side effects of sedation and increased motor weakness associated with antispasticity drugs commonly used for the treatment of multiple sclerosis, no side effects or toxic effects of threonine were identified
These data indicate that modest suppression of the clinical signs of spasticity in a population of patients with MS was achieved with oral administration of threonine. Despite this effect, no improvement in symptoms of spasticity or in global neurologic function was associated with therapy. While the clinical effects observed in this trial do not support the use of threonine in the treatment of MS, the clear reduction of spasticity scores in treated patients suggests that additional studies, employing higher daily dosages or combination therapies, may identify a therapeutic role for this amino acid in the treatment of this disease.